Tildrakizumab for Psoriatic Arthritis

No longer recruiting at 145 trial locations

Overseen By Head, Clinical development

Age: 18+

Sex: Any

Trial Phase: Phase 3

Sponsor: Sun Pharma Global FZE

Must be taking: Anti-TNF agents

Disqualifiers: Active infection, Hepatitis B/C, HIV, others

Pivotal Trial (Near Approval) This treatment is in the last trial phase before FDA approval

Prior Safety Data This treatment has passed at least one previous human trial

Approved in 2 Jurisdictions This treatment is already approved in other countries

Compensation: Varies

Number of Visits: Unknown

Duration: 24 weeks

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial tests a treatment called tildrakizumab to determine its effectiveness for people with active psoriatic arthritis, a condition where the immune system mistakenly attacks the joints, causing pain and swelling. The study compares the effects of tildrakizumab with a placebo (a look-alike inactive substance) to evaluate its effectiveness and safety. People who have tried anti-TNF treatments for psoriatic arthritis or psoriasis (a skin condition that causes itchy, scaly patches) without sufficient relief might be suitable for this trial. As a Phase 3 trial, this study represents the final step before potential FDA approval, offering participants a chance to contribute to the development of a promising new treatment.

Do I need to stop my current medications to join the trial?

The trial protocol does not specify if you need to stop taking your current medications. However, it does require prior exposure to anti-TNF agents for PsO or PsA treatment. Please consult with the study team for more details.

Will I have to stop taking my current medications?

The trial information does not specify if you need to stop taking your current medications. It's best to discuss this with the study team or your doctor.

Is there any evidence suggesting that tildrakizumab is likely to be safe for humans?

Research has shown that tildrakizumab is generally safe. In past studies on plaque psoriasis, researchers found no new safety concerns. For psoriatic arthritis, most participants tolerated the treatment well without serious side effects. However, tildrakizumab is not yet approved specifically for psoriatic arthritis. While it has helped improve joint and skin symptoms, its safety and effectiveness for this condition remain under investigation. ^{1 2 3 4 5}

Why do researchers think this study treatment might be promising for psoriatic arthritis?

Tildrakizumab is unique because it targets a specific protein in the immune system called IL-23, which plays a big role in the inflammation and joint damage seen in psoriatic arthritis. Most current treatments, like TNF inhibitors and methotrexate, work by broadly dampening the immune response, but Tildrakizumab offers a more targeted approach. Researchers are excited about this treatment because it could lead to fewer side effects and improved outcomes for patients by precisely addressing the underlying cause of inflammation in psoriatic arthritis.

What evidence suggests that tildrakizumab might be an effective treatment for psoriatic arthritis?

Research has shown that tildrakizumab, which participants in this trial may receive, holds promise for treating psoriatic arthritis. In earlier studies, it helped at least 20% of patients feel noticeably better, reducing joint pain and improving skin issues related to the condition. Although not yet approved specifically for psoriatic arthritis, these early results are hopeful. Tildrakizumab is already used to treat psoriasis, a condition similar in some ways to psoriatic arthritis. ^{1 3 4 6 7}

Are You a Good Fit for This Trial?

This trial is for adults over 18 with active psoriatic arthritis who've tried anti-TNF agents before. They must not have any current cancer, major blood loss recently, or a history of substance abuse in the last two years. Participants need to use effective birth control and can't be enrolled in another study or have certain infections.

Inclusion Criteria

I have been treated with anti-TNF medications for Psoriasis or Psoriatic Arthritis.

You tested negative for rheumatoid factor and anti-cyclic citrullinated peptide antibodies.

Subject has provided written informed consent.

Exclusion Criteria

Subject previously has been enrolled (randomized) in this study.

I have another active cancer, including skin cancers.

I am currently institutionalized by legal or official order.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive a single dose of tildrakizumab or placebo and are monitored for efficacy and safety

24 weeks

Follow-up

Participants are monitored for safety and effectiveness after treatment

28 weeks

What Are the Treatments Tested in This Trial?

Interventions

• Matching Placebo Injections
• Tildrakizumab

Trial Overview

The trial tests Tildrakizumab (TILD), an investigational medication against a placebo injection to see if it's effective and safe for treating psoriatic arthritis. It's a Phase III study where participants are randomly assigned to receive either TILD or placebo without knowing which one they're getting.

How Is the Trial Designed?

Group I: Arm A Experimental Treatment 1 Intervention

Group II: Arm B Placebo Group 1 Intervention

Tildrakizumab is already approved in European Union, United States for the following indications:

Approved in European Union as Ilumya for:

• Moderate to severe plaque psoriasis

Approved in United States as Ilumya for:

• Moderate to severe plaque psoriasis

Who Is Running the Clinical Trial?

Sun Pharma Global FZE

Lead Sponsor

Trials

34

Recruited

10,200+

Sun Pharmaceutical Industries Limited

Lead Sponsor

Trials

71

Recruited

14,000+

Dilip Shanghvi

Sun Pharmaceutical Industries Limited

Chief Executive Officer since 1993

Majored in Cellular and Molecular Biology at the University of Michigan – Ann Arbor

Dr. Azadar H. Khan

Sun Pharmaceutical Industries Limited

Chief Medical Officer since 2023

MD from a recognized institution

Published Research Related to This Trial

In a phase IIb trial involving 355 adults with moderate-to-severe chronic plaque psoriasis, tildrakizumab demonstrated significant efficacy, with PASI 75 responses of up to 74.4% at week 16 compared to only 4.4% in the placebo group, indicating its effectiveness in reducing psoriasis severity.

Tildrakizumab was generally safe and well tolerated, with serious adverse events reported but not common, suggesting that targeting IL-23p19 could be a promising approach for psoriasis treatment.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial. Papp, K., Thaçi, D., Reich, K., et al.[2018]

In a study of 51 patients with moderate-to-severe plaque psoriasis who had previously failed biologic treatments, tildrakizumab showed significant effectiveness, with a marked reduction in the Psoriasis Area Severity Index (PASI) score from 19.2 at baseline to 0.6 at 48 weeks (P < 0.001).

The treatment also led to substantial improvements in Body Surface Area (BSA) and Dermatology Life Quality Index (DLQI) scores, indicating enhanced quality of life for patients, with significant results observed at both 12 and 48 weeks.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Effectiveness and Safety After a Switch to Tildrakizumab: A Real World Multicenter Italian Study in Psoriasis. Di Brizzi, EV., Buononato, D., Benvenuto, P., et al.[2023]

In a 52-week study involving 237 adults with moderate-to-severe plaque psoriasis, tildrakizumab demonstrated high efficacy, with 90.91% of patients achieving at least a 75% reduction in psoriasis severity (PASI 75) and 58.68% achieving complete skin clearance (PASI 100) by Week 52.

The safety profile of tildrakizumab was favorable, with no significant adverse events reported, and no patients had to discontinue treatment due to side effects, indicating it is a well-tolerated option for psoriasis management in real-life settings.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Real-life effectiveness of tildrakizumab in chronic plaque psoriasis: A 52-week multicentre retrospective study-IL PSO (Italian landscape psoriasis). Narcisi, A., Valenti, M., Gargiulo, L., et al.[2023]

In the TRIBUTE study involving 177 adult patients with moderate-to-severe plaque psoriasis, treatment with Tildrakizumab (TIL) 100 mg for 24 weeks resulted in significant improvements in psoriasis severity, with 88.4% of patients achieving a PASI score of ≤3 and 92.5% achieving PASI 75.

The treatment also led to notable enhancements in health-related quality of life, including reduced pruritus, pain, and improved sleep, with a high patient satisfaction score (mean TSQM score of 80.5), and a favorable safety profile with only one serious adverse event reported.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Tildrakizumab improves high burden skin symptoms, impaired sleep and quality of life of moderate-to-severe plaque psoriasis patients in conditions close to clinical practice. Costanzo, A., Llamas-Velasco, M., Fabbrocini, G., et al.[2023]

In two phase 3 trials involving 1862 patients, tildrakizumab (200 mg and 100 mg) demonstrated significant efficacy in treating moderate-to-severe chronic plaque psoriasis, achieving PASI 75 responses in 62-66% of patients compared to only 6% in the placebo group.

Tildrakizumab was well tolerated, with serious adverse events being low and similar across all treatment groups, indicating a favorable safety profile for this new treatment option.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials. Reich, K., Papp, KA., Blauvelt, A., et al.[2019]

Tildrakizumab, a monoclonal antibody targeting interleukin-23, demonstrated high efficacy in treating moderate to severe psoriasis, with 78% of patients achieving a significant improvement (PASI 75) at 28 weeks in two phase 3 clinical trials.

The treatment showed a favorable safety profile with a low occurrence of adverse events, and its long half-life allows for convenient subcutaneous administration every 12 weeks, making it a practical option for long-term management of psoriasis.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Tildrakizumab for the treatment of psoriasis. Sinclair, R., Thirthar Palanivelu, V.[2020]

Tildrakizumab, an antibody targeting IL-23, was found to be safe and well tolerated in healthy adults, with mild adverse events like upper respiratory infections and headaches reported.

The pharmacokinetics showed that both intravenous and subcutaneous doses resulted in slow clearance and a long half-life, with subcutaneous bioavailability around 80%, indicating effective delivery of the drug.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Pharmacokinetics of Tildrakizumab (MK-3222), an Anti-IL-23 Monoclonal Antibody, After Intravenous or Subcutaneous Administration in Healthy Subjects. Khalilieh, S., Hodsman, P., Xu, C., et al.[2019]

In a study involving 101 patients with ankylosing spondylitis, tildrakizumab did not show a significant improvement in the ASAS20 response rate compared to placebo at week 24, with a response rate of 74.0% for tildrakizumab versus 80.4% for placebo.

The treatment was generally well tolerated, with no unexpected safety issues reported, but the study was terminated early due to the lack of efficacy.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

A Randomized, Double-Blind, Placebo-Controlled Phase 2a Study of Tildrakizumab Efficacy and Safety in Patients With Active Ankylosing Spondylitis. Peters, E., Chou, RC., Rozzo, SJ., et al.[2023]

Tildrakizumab is a monoclonal antibody that specifically targets interleukin-23 p19, which plays a key role in the inflammatory process of chronic plaque psoriasis.

The drug received FDA approval based on positive outcomes from the phase III reSURFACE clinical trial program, demonstrating its efficacy for adults with moderate-to-severe chronic plaque psoriasis who require systemic therapy or phototherapy.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Tildrakizumab: First Global Approval. Markham, A.[2020]

Citations

1.

rheumatologyadvisor.com

rheumatologyadvisor.com/news/tildrakizumab-meets-acr20-endpoint-in-two-psoriatic-arthritis-trials/

Tildrakizumab Meets ACR20 Endpoint in Two Psoriatic ...

Topline data were announced from two phase 3 trials evaluating tildrakizumab in patients with active psoriatic arthritis.

2.

clinicaltrials.gov

clinicaltrials.gov/study/NCT04314544

NCT04314544 | Efficacy and Safety of Tildrakizumab ...

This is a multicenter Phase III, Randomized, Double-Blind, Single-Dose, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of tildrakizumab in ...

3.

sunpharma.com

sunpharma.com/wp-content/uploads/2025/07/Press-Release-Phase-3-Clinical-Studies-PsA-ILUMYA-Topline.pdf

Press-Release-Phase-3-Clinical-Studies-PsA-ILUMYA- ...

Use of tildrakizumab 100 mg (ILUMYA) in psoriatic arthritis is not approved, and its safety and efficacy have not been evaluated by regulatory ...

4.

pubmed.ncbi.nlm.nih.gov

pubmed.ncbi.nlm.nih.gov/33985942/

Efficacy and safety of tildrakizumab in patients with active ...

Conclusions: Tildrakizumab treatment significantly improved joint and skin manifestations of PsA other than dactylitis and enthesitis. Treatment ...

5.

ilumyapro.com

ilumyapro.com/ilumya-results

Pivotal Trial Data | ILUMYA® (tildrakizumab-asmn)

ILUMYA® PIVOTAL TRIAL RESULTS THROUGH 5 YEARS · ILUMYA® (tildrakizumab-asmn) provided consistent reduction of detectable psoriasis activity throughout the 5-year

6.

clinicaltrials.gov

clinicaltrials.gov/study/NCT04314531

NCT04314531 | Efficacy and Safety of Tildrakizumab ...

This is a randomized, double-blinded, placebo-controlled, Phase 3 study to evaluate the efficacy and safety of tildrakizumab compared to placebo in anti-TNF ...

7.

ard.bmj.com

ard.bmj.com/content/80/9/1147

Efficacy and safety of tildrakizumab in patients with active ...

Conclusions Tildrakizumab treatment significantly improved joint and skin manifestations of PsA other than dactylitis and enthesitis. Treatment was generally ...